A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel group, phase 2 study to compare the efficacy and safety of masitinib versus placebo on cognitive impairment associated with Parkinson's disease
Latest Information Update: 04 Nov 2019
At a glance
- Drugs Masitinib (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors AB Science
- 24 Sep 2019 Status changed from completed to suspended.
- 20 Mar 2017 New trial record